Bear markets are a time of significant volatility; the tide goes out, and virtually all stocks can fall, regardless of whether they're strong companies. The trick is identifying the damaged stocks with solid business fundamentals behind them because they're most likely to rebound, soaring to new highs over time.

Genetics company Invitae (NYSE: NVTA) is one of the early movers in genetic testing, a stock with immense potential. But there are risks to consider; down a staggering 95% from its high, here is why investors should consider Invitae a speculative investment.

Genetic testing could play a huge role in the long-term future of healthcare. Precedence Research estimates the market could grow from $7.5 billion in 2020 to nearly $14 billion by 2030.

Continue reading

Source Fool.com